Get started

Value

$PEP Bullish Swing Setup – Oversold & Ready to Rebound ?PepsiCo ( NASDAQ:PEP ) is sitting at a major long-term support after a deep pullback — this could be a strong opportunity for a risk-defined bounce. Here's what the chart is signaling: 🔹 Entry Zone: Price is currently near $128 — a historically significant level that acted as resistance in the past and now aligns with a potential support flip. 🔹 Oversold & Stretched: After a consistent downtrend, NASDAQ:PEP is looking oversold. A bounce is likely as sellers exhaust and dip buyers return at this key level. 🔹 Reversal Structure Building: Early signs of a bottoming pattern are emerging, with potential higher lows forming. If the current structure holds, we could see a climb toward the next resistance zones. 🎯 Targets: TP1: $154 – minor resistance and previous consolidation zone. TP2: $197 – major resistance and range high, aligning with earlier highs. 🛡️ Stop Loss: Below $102 — invalidates the support thesis and breaks structure. 💡 Why Price May Rise: PEP is a defensive name with strong fundamentals, often benefiting during uncertain macro cycles. Valuation is now more attractive after the sell-off. The setup offers a high reward-to-risk ratio, especially if broader markets stabilize. ⚖️ Setup Summary: Entry: ~$128 SL: $102 TP1: $154 TP2: $197 📌 Watching for confirmation with volume or bullish candle structure over the next few sessions. 🚫 Not financial advice — just a technical outlook based on structure and probability.
NASDAQ:PEPLong
by Kristjan_Maximus
A BNPL Bubble Is Actually Why I'm Bullish, For NowBNPL is growing and inflating at an increasing rate. From concert tickets to burritos, everyone is using buy now pay later. The global market is projected to hit 560 billion dollars in 2025, up from around 492 billion in 2024, and climb to 912 billion by 2030 at a compounding growth rate of 10.2%. Just in the U.S. alone, demand is expected to reach 122 billion next year and scale to 184 billion by the end of the decade. The trajectory is steep, with the structural weaknesses already showing. Block is positioned at the center of BNPL. In Q1 2025 they reported: 2.29 billion in gross profit, up 9 percent YoY 466 million in adjusted operating income, up 28% 10.3 billion in GMV through Afterpay, with 298 million in BNPL gross profit, up 23% YoY The stock took a hit. It dropped 9 percent in February and another 21 percent after missing Q1 earnings, but this is seen as typical early bubble behavior. There is short term fear but continuing growth and acceleration. Klarna’s credit losses, IPO delays, and regulatory friction are not problems, they are actually signals that the sector is growing faster than the market, or quite frankly, anyone can control. BNPL is becoming the default credit system for younger consumers. It is overused and expanding too fast. That is the formula for both upside and implosion. However with that, timing will be everything here. Baseline expectation: SQ trades in the 80 to 90 range in the short term Midterm upside: 120 by 2027 Long-term target: 180 to 220 if BNPL stabilizes and Block captures its runway
NYSE:XYZLong
by chrisapach
NewtekOne | NEWT | Long at $10.92NewtekOne NASDAQ:NEWT is a financial holding company providing business and financial solutions to small- and medium-sized businesses across the U.S. Services include Newtek Bank, business lending, SBA loans, electronic payment processing, payroll and benefits, insurance, and technology solutions. While the stock has taken a major hit recently, insiders have scooped up over $1 million in shares with an average price of $11.70. Currently trading at a P/E of 5.6x, forward P/E of 6.6x, and near book value, the stock may be poised for a move up soon with the anticipation of interest rates dropping. Revenue is up 24.93% from $271.15M (2023) to $338.73M (2024) and earnings are forecast to grow 11.63% per year, but the company does have a high debt-to-equity ratio (over 5x). Tariffs could indirectly impact NASDAQ:NEWT by increasing costs for its small- and medium-sized business clients, particularly in industries reliant on imports (e.g., manufacturing, retail). Higher costs may reduce client profitability, increasing loan default risks or reducing demand for Newtek’s lending and payment processing services. But an interest rate reversal may greatly limit the impact (longer-term). So, at $10.92, NASDAQ:NEWT is in a personal buy zone. Targets into 2027: $12.00 (+9.9%) $14.00 (+28.2%)
NASDAQ:NEWTLong
by WorthlessViews
Oxford Industries | OXM | Long at $38.10Oxford Industries NYSE:OXM is an apparel company that designs, sources, markets, and distributes lifestyle brands like Tommy Bahama, Lilly Pulitzer, and Southern Tide. While I am not super bullish on the retail sector given the blaring recession signals, I also don't think this is the end of life as we know it... the anticipated downside is already priced-in for many retail brands. From a technical analysis perspective, NYSE:OXM has entered my "crash" simple moving average zone. Typically, but not always, this is an area where value investors accumulate shares in anticipation of a future rise in share price. While the price is likely to dip near $28-$30 in the near-term, the last open price gap on the daily chart since the COVID-19 pandemic was closed today. Also, last week, an NYSE:OXM Officer and the CEO bought just over $600,000 in shares near $40 and the stock is currently trading at book value. Fundamentals: P/E = 7.4x (apparel sector average = 22.4x) Forward P/E = 11.4x Dividend = 7.25% Debt-to-equity = .2x (healthy) Regardless of some strong fundamentals, persistent macro volatility, consumer caution, and tariff pressures may delay recovery. Analysts expect flat to declining sales in 2025, with limited organic growth. Like I mentioned above, while there is likely short-term pain here, the fundamentals are there to potentially weather the storm. Thus, at $38.10, NYSE:OXM is in a personal buy zone with the further decline between $28-$30 likely (where additional share accumulation will occur as long as the fundamentals do not change). Targets into 2027 $45.00 (+18.0%) $50.00 (+31.2%)
NYSE:OXMLong
by WorthlessViews
Stellantis | STLA | Long at $9.59Stellantis NYSE:STLA is the maker of the auto brands Fiat, Peugeot, Jeep, Citroën, Opel/Vauxhall, Ram Trucks, Dodge, Chrysler, Alfa Romeo, Maserati, DS Automobiles, Lancia, Abarth, and Vauxhall. The stock has fallen sharply due to a 70% profit drop in 2024, weak U.S. sales, high inventory, and tariff uncertainties. The turnaround for NYSE:STLA beyond 2025 hinges on new CEO Antonio Filosa’s focus on U.S. market recovery, new product launches (e.g., Ram 1500 Ramcharger, Jeep hybrids), pricing adjustments, aggressive marketing, $5B U.S. manufacturing investment, and mending dealer relations. The stock is trading at a P/E of 5.1x, debt-to-equity of 0.8x (not bad), a book value of $29 (undervalued), a tangible book value of $9.82, and earnings and revenue are forecasted to grow into 2028. Economic weakening and tariffs may hamper these predictions, but the new CEO and future interest rate drops may get this stock rolling again. However, if NYSE:STLA shows zero sign of near-term recovery or other fundamental issues arise, I truly think this stock could enter the high $5-$6 range before a true reversal begins. From a technical analysis perspective, the stock price is currently with my selected "crash" simple moving average. This area often signifies a near-term bottom, but like mentioned above, watchout out for the "major crash" simple moving average area currently between $5.83 and $7.09. Regardless of bottom predictions, NYSE:STLA is in a personal buy zone at $9.59 with a greater position likely if it enters my "major crash" zone, as mentioned above. Targets into 2027: $12 (+25.1%) $14 (+46.0%)
NYSE:STLALong
by WorthlessViews
Diageo | DEO | Long at $101.15Diego NYSE:DEO is the owner of alcohol brands such as Johnnie Walker, Crown Royal, Smirnoff, Baileys, Guinness, Tanqueray, Don Julio, Cîroc, and Captain Morgan. The stock has fallen significantly since 2021 due to several factors, such as: post-COVID recovery slowdown; retail/travel disruptions hurting high-margin segments; inflationary pressures raising costs for materials like glass and agave, squeezing margins; consumer downtrading to cheaper alternatives; and macroeconomic headwinds. While tariffs may prolong overall recovery, I do not think it's the end for this company by any means. Factors likely to drive NYSE:DEO stock higher include: Interest Rate Cuts : Expected U.S. rate cuts in 2025 could boost consumer confidence and spending, benefiting premium brands. Lower rates may also reduce debt costs, easing pressure on its debt load. Productivity Initiatives : NYSE:DEO $2B savings program (2025-2027) aims to improve efficiency, margins, and cash flow, potentially restoring investor confidence. Undervaluation : Trading at 17.5x forward earnings (below historical 21x), the stock may attract value investors. From a technical analysis perspective, NYSE:DEO has been riding my "crash" simple moving average zone. While the momentum has a strong downtrend, entry into this "crash" zone typically only happens a few times before a trend reversal. But there is a good probability, that my "major crash" zone (currently in the $80s) is possible before a true reversal. Regardless, without a crystal ball, I am starting to form a position and plan to add more if the "major crash" happens with this stock. Thus, at $101.15, NYSE:DEO is in a personal buy zone with the noted potential for a drop into the $80s due to projected earnings revisions, etc. Targets into 2027: $120.00 (+18.6%) $140.00 (+38.4%)
NYSE:DEOLong
by WorthlessViews
Beeline Holdings | BLNE | Long at $0.72**This is a VERY risky penny stock. Please do not invest if you are risk averse.** Beeline Holdings NASDAQ:BLNE Book value = $5.00-$6.00 Revenue past 12 months: $5.21 million (grew by 27.4% over the past year) Debt-to-equity: 0.21x (low) Insiders purchased almost $500k in shares in the past 6 months and volume increasing 6 million float, 1.96% short interest, 0.85 days to cover This is purely a gamble play based on value and insider purchases. Thus, at $0.72, NASDAQ:BLNE is in a personal buy zone. Targets: $1.00 $1.25
NASDAQ:BLNELong
by WorthlessViews
XRP Price Finds Some Relief — But Headwinds Remain,Says ArtavionAfter slipping below $0.50 last week, XRP has rebounded modestly, now trading above $0.52. While this short-term recovery provides relief for holders, fundamental and structural challenges still limit the token’s upside potential, according to analysts at Artavion. The recent bounce appears largely technical. Support held near $0.48, and with Bitcoin regaining strength above $66,000, sentiment across altcoins briefly improved. XRP’s Relative Strength Index (RSI) has moved out of oversold territory, suggesting some room for additional upside — but resistance between $0.56 and $0.60 remains firm. Low trading volume suggests the rally lacks conviction. A major ongoing concern remains XRP’s legal battle with the U.S. Securities and Exchange Commission (SEC). Although Ripple Labs scored partial wins, the case is unresolved. Until a final judgment or settlement is reached, institutional investors will likely remain cautious, and U.S.-based platforms will continue restricting XRP exposure. 🗨️ “The legal cloud hasn’t lifted — and that limits capital inflows,” says a regulatory analyst at Artavion. From a network perspective, XRP Ledger remains functional and Ripple’s payment infrastructure is active, particularly in select cross-border corridors. However, XRP still lacks integration with key crypto sectors like DeFi, NFTs, and gaming, which restricts organic demand and developer activity. Externally, macro conditions are neutral to negative for altcoins. The Federal Reserve’s rate outlook and rising bond yields continue to pressure speculative assets. Stablecoin inflows into XRP trading pairs have slowed — another signal of fading short-term appetite. Outlook At Artavion, we believe XRP is currently locked in a range-bound pattern. A breakout above $0.60 is unlikely without: Full legal clarity in the U.S.; Stronger altcoin sentiment market-wide; Renewed ecosystem development and integrations. 🗨️ “XRP isn’t broken — it’s waiting,” says the Artavion market desk. “But without a catalyst, it stays reactive — not directional.”
CRYPTOCAP:XRP
by HCN-News12
SOL Long Term Long PositionJSE:SOL credit rating has been stamped with a Ba1 by Moody's which is very unfavourable to the company, wholistically. This is as a result of its weakening operating performance mainly attributed to low demand in the chemicals market and weak oil prices. With expectations of higher FX:USOIL prices and JSE:SOL being pretty much undervalued, trading near its supporting level of 8600 ZAC, a positive outlook is still evident. Long positions have been executed at 9574 ZAC with a possibility to further capitalize when necessary. Cite: Sasol outlook downgraded to negative by Moody's Ratings, Ba1 rating affirmed - Luke Juricic
JSE:SOLLong
by Dlamini_SS
Trade Ideas For GOLD: Long and Short TRADE IDEA FOR SHORTS: Price may try to sell at Previous Day's High. It may reject PDH following the order flow. US involvement will boost the metals. Trump may announce or strike on the weekend. TRADE IDEA FOR LONGS: The unmitigated demand level has broken structure. Buyers here created new highs. So there may be a willingness to buy again from this level, considering the looming US involvement in Iran Israel war. I would be targeting the unmitigated sellers' block at 3.410.21
EASYMARKETS:XAUUSD
by simplestupid
Wedge Breakout in Motion – 317% Potential Toward Channel Up📍 Ticker: NASDAQ:ACB (Aurora Cannabis Inc.) 📆 Timeframe: 1D (Daily) 📉 Price: $4.71 📊 Volume: 1.22M 📈 RSI: 42.76 (rising from oversold territory) 🔍 Technical Setup: After years of decline, NASDAQ:ACB has broken out of a large descending wedge, with price pushing above downtrend resistance and reclaiming horizontal support. 🔼 Breakout Structure: Descending wedge + horizontal base 📉 Bear market floor established at ~$3.00 📈 Next key level: ~$5.60, then $9.00+ 💠 Price projection drawn within expanding ascending channel, targeting mid-to-upper range reversion over time. 🧠 Trade Plan & Price Targets: ✅ Entry Zone: $4.60–$4.80 (confirmed breakout, medium risk) ✅ Entry Zone: $3.60–$3.80 (full gap retest, lower risk) ✅ Entry Zone: $2.95–$3.10 (Lowest low, lowest risk) ❌ Stop-Loss: Close below $4.00 (failed retest + support invalidation) ❌ Stop-Loss 2: Close below $3.55 (Lower than the biggest gap low level) ❌ Stop-Loss 3: Close below $2.84 (Lower than the lowest low) 🎯 Target 1: $5.60 → 📈 Return: +18.9% 🎯 Target 2: $9.00 → 📈 Return: +91.0% 🎯 Target 3: $15.00 → 📈 Return: +217.0% ⚠️ Key Insights: RSI curling up from below 40 = momentum shift Short interest remains high → potential short squeeze trigger Price is now above long-term downtrend — trend reversal scenario in play Macro sentiment toward cannabis may act as catalyst Still haven't started the biggest US market 💬 Can Aurora Cannabis light up again and return to its long-term channel highs? Follow for more setups with asymmetric risk/reward. #TargetTraders #ACB #CannabisStocks #WedgeBreakout #ChannelReversion #PennyStockSetup
NASDAQ:ACBLong
by TargetTraders
Greer Free Cash Flow Yield (FCF%) — Long-Term Value Signal✅ Title Greer Free Cash Flow Yield (FCF%) — Long-Term Value Signal 📝 Description The Greer Free Cash Flow Yield indicator is part of the Greer Financial Toolkit, designed to help long-term investors identify fundamentally strong and potentially undervalued companies. 📊 What It Does Calculates Free Cash Flow Per Share (FY) from official financial reports Divides by the current stock price to produce Free Cash Flow Yield % Tracks a static average across all available financial years Color-codes the yield line: 🟩 Green when above average (stronger value signal) 🟥 Red when below average (weaker value signal) 💼 Why It Matters FCF Yield is a powerful metric that reveals how efficiently a company turns revenue into usable cash. This can be a better long-term value indicator than earnings yield or P/E ratios, especially in capital-intensive industries. ✅ Best used in combination with: 📘 Greer Value (fundamental growth score) 🟢 Greer BuyZone (technical buy zone detection) 🔍 Designed for: Fundamental investors Value screeners Dividend and FCF-focused strategies 📌 This tool is for informational and educational use only. Always do your own research before investing.
NYSE:CMGLong
by controllinghand
MGP Ingredients | MGPI | Long at $29.57MGP Ingredients NASDAQ:MGPI has been in "crash" phase since 2023 due to lower U.S. liquor consumption, a whiskey glut, a CEO resignation, a facility closure, and a shift to higher-margin business. While currently trading near $30, the book value is at $39, forward price-to-earnings is 8x, debt-to-equity is 0.4x (low), and some insiders have been awarded stocks and options (although, selling has been rather high, too). Earnings and revenue are expected to grow slowly beyond 2025, but this year is anticipated to be the worst in some time. The low expectations may already be priced in, but time will tell. While I do not plan to be a long-term holder of the stock, the price is within my "crash" simple moving average area and the fundamentals aren't terrible. If interest rates are lowered within the next year, I believe this could begin the turnaround for the company (although slow). Thus, at $29.57, NASDAQ:MGPI is in a personal buy zone for a swing trade. Targets: $35.00 (+18.4%) $40.00 (+35.3%)
NASDAQ:MGPILong
by WorthlessViews
Integra LifeSciences Holdings | IART | Long at $12.39Integra LifeSciences Holdings Corp NASDAQ:IART manufactures and sells surgical instruments, neurosurgical products, and wound care solutions for neurosurgery, neurocritical care, otolaryngology, orthopedics, and general surgery. The stock has fallen over the past few years due to earnings misses / lowered earnings per share guidance, slow revenue growth, and operational challenges / recalls. But the company has been around since 1989 (endured many ups and downs during that time), has over 4,000 employees, a book value near $20 (undervalued), a forward price-to-earnings between 6x-9x (depending on the source), and revenue growth beyond 2025 and into 2028. Debt is slightly high with a debt-to-equity ratio of 1.2x and a quick ratio near 0.8x (company may have difficulty meeting its short-term obligations with its most liquid assets), it is thus a risky play. But the valuation and potential turnaround should get some attention. From a technical analysis perspective, the stock price has entered and exited my "crash" simple moving average area 3 times now (see green lines). While I think $10 is likely in the near-term, it appears the stock *may* be forming a bottom - especially given the book value is more than 60% from the current price. But, as always, medical device stocks are always a major investment risk, so due diligence is needed. Thus, at $12.39, NASDAQ:IART is in a buy zone with a note regarding the potential for a dip near $10 before a move up. Targets will be kept low for a swing trade. Targets: $15.00 (+21.0%) $16.50 (+33.2%)
NASDAQ:IARTLong
by WorthlessViews